STOCK TITAN

Can-Fite (CANF) director discloses option grants and share stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. director Regev Guy filed an initial ownership statement showing direct holdings of options to purchase Ordinary Shares and a small number of shares. He reports options over 16,000 shares at an exercise price of $2.18 per share plus several smaller, higher-priced option grants and 8 Ordinary Shares. The options were granted under the company’s share option plans, with some fully vested and others vesting in scheduled quarterly installments through 2030.

Positive

  • None.

Negative

  • None.
Insider Regev Guy
Role Director
Type Security Shares Price Value
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Options to Purchase Ordinary Shares — 16 shares (Direct); Ordinary Shares — 8 shares (Direct)
Footnotes (1)
  1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee. These options are fully vested and exercisable as of the date hereof. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 8,778, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 1,489 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date. The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none are vested, and all the 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
Low-priced options 16,000 options at $2.18 Exercise price; options vest from 04/25/2026 to 01/25/2030
Option grant 2,166 options at $26.56 Exercise price; expiration 05/07/2034
Option grant 2,166 options at $25.21 Exercise price; expiration 04/30/2033
Option grant 200 options at $241.47 Exercise price; expiration 06/14/2030
Option grant 16 options at $2,826.14 Exercise price; expiration 11/08/2027
Ordinary Shares 8 shares Directly held Ordinary Shares following the reported holdings
Section 102 of the Israeli Tax Ordinance financial
"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee..."
Share Option Plan financial
"in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan..."
exercise price financial
"The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 8,778..."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"Of the options reported herein 1,489 options are vested, and the remaining 1,489 options vest in five equal quarterly installments..."
Ordinary Shares financial
"underlying_security_title": "Ordinary Shares""
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Regev Guy

(Last)(First)(Middle)
C/O CAN-FITE BIOPHARMA LTD.
26 BEN GURION STREET

(Street)
RAMAT GAN NEVADA 5257346

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]
3a. Foreign Trading Symbol
[CANF.TA]
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares8D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to Purchase Ordinary Shares(1)(2)02/08/201711/08/2027Ordinary Shares16(2)$2,826.14(3)D
Options to Purchase Ordinary Shares(1)(2)06/15/202006/14/2030Ordinary Shares200(2)$241.47(4)D
Options to Purchase Ordinary Shares(1)(5)08/01/202304/30/2033Ordinary Shares2,166(5)$25.21(5)D
Options to Purchase Ordinary Shares(1)(6)08/07/202405/07/2034Ordinary Shares2,166(6)$26.56(6)D
Options to Purchase Ordinary Shares(1)(7)04/25/202601/25/2030Ordinary Shares16,000(7)$2.18(7)D
Explanation of Responses:
1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
2. These options are fully vested and exercisable as of the date hereof.
3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 8,778, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
4. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
5. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,489 options are vested, and the remaining 1,489 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
6. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 947 options are vested, and the remaining 1,219 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
7. The exercise price of this option, originally denominated in NIS in the amount of NIS 6.767, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein, none are vested, and all the 16,000 options vest in sixteen equal quarterly installments beginning 04/25/2026 and ending 01/25/2030 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
/s/ Guy Regev04/06/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Can-Fite (CANF) director Regev Guy report on this Form 3?

He reports his initial ownership in Can-Fite securities, mainly options to purchase Ordinary Shares plus 8 Ordinary Shares. The filing lists each option grant’s exercise price, expiration date, and vesting status under the company’s share option plans, establishing his baseline position.

How many Can-Fite (CANF) options at the lowest exercise price does Regev Guy hold?

He holds options over 16,000 Ordinary Shares at an exercise price of $2.18 per share. Footnotes state none of these options are vested yet and they vest in sixteen equal quarterly installments from 04/25/2026 through 01/25/2030, subject to continued service.

Are Regev Guy’s Can-Fite (CANF) options already vested or still vesting?

Some options are fully vested and exercisable, while others vest over time. For example, 1,489 of certain options are vested with the remainder vesting in five quarterly installments, and another grant vests in nine quarterly installments, all conditional on continued service with Can-Fite.

Why are Can-Fite (CANF) options held through a trustee under Section 102?

To qualify for specific Israeli tax benefits under Section 102 of the Israeli Tax Ordinance, employee securities under Can-Fite’s 2003, 2013, and 2023 Share Option Plans must be registered in a trustee’s name. This structure is tax-driven and does not change the reported economic interest.

What are the exercise prices of Regev Guy’s higher-priced Can-Fite (CANF) options?

He holds smaller grants with exercise prices of $2,826.14, $241.47, $25.21, and $26.56 per share. These prices were originally set in New Israeli Shekels and converted to U.S. dollars using a NIS 3.106 = USD 1.00 exchange rate.